about
Implication of microRNAs in atrial natriuretic peptide and nitric oxide signaling in vascular smooth muscle cellsA miRNA-driven inference model to construct potential drug-disease associations for drug repositioningmiR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway.Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance.Pharmaco-miR: linking microRNAs and drug effects.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Tailoring mTOR-based therapy: molecular evidence and clinical challenges.MicroRNAs: Meta-controllers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human diseaseClinically relevant genetic variations in drug metabolizing enzymes.MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neckMicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines.Analysis for the mechanism between the small cell lung cancer and non-small cell lung cancer combing the miRNA and mRNA expression profiles.miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle.Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine.Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs.The Promises of Quantitative Proteomics in Precision MedicineMechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters.Toxicological implications of modulation of gene expression by microRNAs.Role of miRNA in head and neck squamous cell carcinoma.Regulation of Pharmacogene Expression by microRNA in The Cancer Genome Atlas (TCGA) Research Network.Effect of Narrow-Band Ultraviolet B Phototherapy and Methotrexate on MicroRNA (146a) Levels in Blood of Psoriatic PatientsmiR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.MiR-34c oligonucleotide enhances chemosensitivity of Ishikawa cell to cisplatin by inducing apoptosis.Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers.MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.Role of epigenetic and miR-22 and miR-29b alterations in the downregulation of Mat1a and Mthfr genes in early preneoplastic livers in rats induced by 2-acetylaminofluorene.miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1.MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action.miRDDCR: a miRNA-based method to comprehensively infer drug-disease causal relationships.Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors.In Vitro Validation of miRNA-Mediated Gene Expression Linked to Drug Metabolism.miR-34 modulates apoptotic gene expression in Ingenol mebutate treated keloid fibroblasts.Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement
P2860
Q28392601-705291AA-FAFF-4841-9441-412DFA6DD6BAQ28652746-EF919C7C-2A22-4306-8BC1-2388FD207C16Q32179160-24AA2B2B-1130-4DB8-AC92-AD1BE52AD20DQ33708471-F55A4856-2490-462F-9B23-B815C595C68AQ33920265-6458C218-BCF5-46DA-B59D-C73356ACB9ADQ33993320-FEF152E8-CC3C-4FF7-BCC8-0C5C29B5CB85Q34294170-2101FD81-C3AD-4AD5-902E-E23C32959AB6Q34594189-E2D62C0E-BC1C-4491-A6EB-7ABF59A24910Q35032378-173B2495-9EA9-4E0C-96D4-D273D3B21325Q35051089-2E6A7482-F80C-4B70-B9D1-8E9836D80C23Q35171243-495EF071-0548-461A-84CF-9CDDFF05E46BQ35663529-A5B0143A-4C57-4E38-A7F3-8FE5791A1C02Q36585627-06B8A49D-A594-406B-987F-832EA7FF5A87Q36754038-519E9149-14D5-4811-AA73-E27F236990B7Q37564492-2EC04D11-0FE9-4F39-9220-B980E2F175FEQ37647264-E6330445-1C53-4605-A050-DA1A889B7CBEQ37791990-F7E58631-3CC5-43B4-8F1D-1EB1B8997692Q37895810-849D3477-CCE3-4805-85E8-5CC89B69F209Q38264776-9E62077A-943F-4FE0-922E-B9D610056BEEQ38611444-C21487A7-D45C-42AD-933D-A9AEBAE24B25Q38938889-7BF1C5D8-9FC0-489F-BD55-B6790D4685FCQ39125450-021B4195-62B3-471E-A071-9B5EE753805DQ39193935-0BDC16C4-39C8-4654-9B3D-527696D9B561Q39293823-72190AAD-D5AE-4108-A582-DAE1497C49C1Q39359970-70DE814A-A646-4795-A995-1C288D1A2C9EQ39418606-2DD3B890-13FA-4795-AE12-65584AD4A100Q45044001-5A97F141-FFD8-4951-AAB4-75FD77922656Q47118154-E03609E2-BD21-4D47-9F27-E727FE9406F3Q47137904-0AA61CB1-217C-415B-A7C4-CCA4B9B2CD32Q47552152-82C16B77-38FD-4767-A09C-E18B1EFC04FEQ52407682-61E68E71-3EA4-406A-AFA7-48D019492A7DQ52641301-E73A8188-73F1-4520-B255-E179DD60F445Q55654316-65A45083-732A-4F01-B34C-F3C061B6BC4AQ57500191-2CE1254E-6D5B-4D65-96A7-58B1AC70EEAB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MicroRNAs and pharmacogenomics.
@en
MicroRNAs and pharmacogenomics.
@nl
type
label
MicroRNAs and pharmacogenomics.
@en
MicroRNAs and pharmacogenomics.
@nl
prefLabel
MicroRNAs and pharmacogenomics.
@en
MicroRNAs and pharmacogenomics.
@nl
P2860
P356
P1433
P1476
MicroRNAs and pharmacogenomics.
@en
P2093
Noam Shomron
P2860
P304
P356
10.2217/PGS.10.26
P577
2010-05-01T00:00:00Z